ISBN: 9783319090740 - optimization of pharmaceutical r&d programs and portfolios: design and investment strategy (4 Ergebnisse)

ISBN: 
Mit der Detailsuche verfeinern

Optimieren Sie Ihre Suche

  • Bücher (4)

  • Neu (4)

bis

Benutzerdefinierte Preisspanne (EUR)

bis

  • Sprache: Englisch

    Verlag: Springer, 2014

    3319090747 / 9783319090740

    • Hardcover

    Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes KönigreichRia Christie Collections

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 229,25

    EUR 13,44 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: Mehr als 20 verfügbar

    Zustand: New. In English.

  • Sprache: Englisch

    Verlag: Springer, 2014

    3319090747 / 9783319090740

    • Hardcover

    Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 242,59

    EUR 35,00 Versand 
    Versand von Deutschland nach USA

    Anzahl: 1 verfügbar

    Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Very little has been published on optimization of pharmaceutical portfolios. Moreover, most of published literature is coming from the commercial side, where probability of technical success (PoS) is treated as fixed, and not as a consequence of development strategy or design. In this book there is a strong focus on impact of study design on PoS and ultimately on the value of portfolio. Design options that are discussed in different chapters are dose-selection strategies, adaptive design and enrichment. Some development strategies that are discussed are indication sequencing, optimal number of programs and optimal decision criteria.This book includes chapters written by authors with very broad backgrounds including financial, clinical, statistical, decision sciences, commercial and regulatory. Many authors have long held executive positions and have been involved with decision making at a product or at a portfolio level. As such, it is expected that this book will attract a very broad audience, including decision makers in pharmaceutical R&D, commercial and financial departments. The intended audience also includes portfolio planners and managers, statisticians, decision scientists and clinicians.Early chapters describe approaches to portfolio optimization from big Pharma and Venture Capital standpoints. They have stronger focus on finances and processes. Later chapters present selected statistical and decision analysis methods for optimizing drug development programs and portfolios. Some methodological chapters are technical; however, with a few exceptions they require a relatively basic knowledge of statistics by a reader.…

  • Sprache: Englisch

    Verlag: Springer, 2014

    3319090747 / 9783319090740

    • Hardcover

    Anbieter: Home-set, Mannheim, DeutschlandHome-set

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 267,49

    EUR 49,90 Versand 
    Versand von Deutschland nach USA

    Anzahl: 2 verfügbar

    Gebundene Ausgabe. Zustand: Neu. Very little has been published on optimization of pharmaceutical portfolios. Moreover, most of published literature is coming from the commercial side, where probability of technical success (PoS) is treated as fixed, and not as a consequence of development strategy or design. In this book there is a strong focus on impact of study design on PoS and ultimately on the value of portfolio. Design options that are discussed in different chapters are dose-selection strategies, adaptive design and enrichment. Some development strategies that are discussed are indication sequencing, optimal number of programs and optimal decision criteria.This book includes chapters written by authors with very broad backgrounds including financial, clinical, statistical, decision sciences, commercial and regulatory. Many authors have long held executive positions and have been involved with decision making at a product or at a portfolio level. As such, it is expected that this book will attract a very broad audience, including decision makers in pharmaceutical R&D, commercial and financial departments. The intended audience also includes portfolio planners and managers, statisticians, decision scientists and clinicians.Early chapters describe approaches to portfolio optimization from big Pharma and Venture Capital standpoints. They have stronger focus on finances and processes. Later chapters present selected statistical and decision analysis methods for optimizing drug development programs and portfolios. Some methodological chapters are technical; however, with a few exceptions they require a relatively basic knowledge of statistics by a reader. Sprache: Englisch Gewicht in Gramm: 437.…

  • Sprache: Englisch

    Verlag: Springer Verlag, 2014

    3319090747 / 9783319090740

    • Hardcover

    Anbieter: Revaluation Books, Exeter, Vereinigtes KönigreichRevaluation Books

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 314,75

    EUR 14,98 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: 2 verfügbar

    Hardcover. Zustand: Brand New. 2015 edition. 202 pages. 9.25x6.25x0.75 inches. In Stock.